Clearmind Medicine (CMND) Fundamental Analysis: Revenue, Earnings & Valuation

0.62 / 10

Underperform

Fundamental rating is Underperform with a 0.6/10 score. Asset and revenue metrics are modestly positive, but profit‑margin, net income and cash flow ratios are deeply negative, indicating weak earnings quality and high risk.

Analysis Checks(3/10)

Revenue-MV

Value-0.11

Score3/3

Weight-14.00%

1M Return3.85%

Net cash flow from operating activities / Operating revenue (%)

Value-982.50

Score0/3

Weight23.73%

1M Return-9.58%

Profit-MV

Value0.66

Score1/3

Weight8.42%

1M Return-2.85%

Net income-Revenue

Value-0.04

Score1/3

Weight7.54%

1M Return-2.58%

Net profit margin (%)

Value-1264.47

Score0/3

Weight23.23%

1M Return-9.31%

Cash-UP

Value-0.15

Score3/3

Weight-8.85%

1M Return2.45%

Net cash flow from operating activities / Total liabilities (%)

Value-0.97

Score0/3

Weight16.99%

1M Return-6.78%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight22.73%

1M Return-9.03%

Asset-MV

Value-0.55

Score2/3

Weight-3.02%

1M Return0.95%

Net profit / Total operating revenue (%)

Value-654.10

Score0/3

Weight23.23%

1M Return-9.31%

Is CMND undervalued or overvalued?

CMND scores 0.62/10 on fundamentals and holds a Premium valuation at present. Backed by its -81.74% ROE, 0.00% net margin, -0.34 P/E ratio, 0.27 P/B ratio, and 41.67% earnings growth, these metrics solidify its Underperform investment rating.